+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Japan Electroceuticals Market 2019-2025

  • PDF Icon


  • January 2020
  • Region: Japan
  • Orion Market Research Private Limited
  • ID: 4969110
UP TO OFF until Dec 31st 2022

Japan is contributing significantly to the electroceuticals market. Geriatric population is one of the major concerns for the Japanese government and other healthcare institution. Out of total 126 million population, about 27% population of the country was above 65 years in 2017. It is forecast that the population will reduce to 123 million in 2023 and geriatric population is forecast to be higher as compared to 2017. Additionally, life expectancy of the people in Japan is the highest globally. The incidence of heart stroke occurrence in geriatric population is relatively high as compared to young population. As per the Institute for Health Metrics and Evaluation, in 2017, around 0.2 million incidences of ischemic heart disease occurred in Japan. The prevalence of Ischemic heart disease in 2013 was 3.5 million peoples that have increased to 3.7 million in 2017.

The other major factor that provides significant growth to the market is product approval in the country. Companies such as Sorin CRM SAS, Century Medical, Inc., Medtronic Japan Company Limited, and St. Jude Medical Japan Company Limited, have received their product approval from the government regulatory bodies in the FY 2018 and FY 2019. Neurostimulators, pacemakers, and defibrillators are the major electroceuticals approved by the government, however, only a single new cochlear implant approval has been observed during the tracking period. The results of foreign clinical studies were also submitted to evaluate the efficacy and safety of the electroceuticals in the country for various electroceuticals.

LivaNova had received Japan's Ministry of Health, lab our& Welfare approval for Perceval suture less aortic heart valve to treat aortic valve disease that enables to provide patients and clinicians in Japan with a new option for aortic heart valve replacement. Additionally, the company had received the US FDA 510(k) clearance of the MEMO4D semi-rigid mitral annuloplasty ring and confirmed the first implantation of the device.

Research Methodology

The market study of the Japan Electroceuticals market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for medical device manufacturing companies, distributors and suppliers, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Japan Electroceuticals Market Research and Analysis by Product

2. Japan Electroceuticals Market Research and Analysis by End-users

The Report Covers

  • Comprehensive research methodology of the Japan electroceuticals market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Japan electroceuticals market.
  • Insights about market determinants which are stimulating the Japan electroceuticals market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Japan Electroceuticals Market by Product and its Application
5.1.1. Cardioverter Defibrillators and Cardiac Pacemaker Arrhythmias
5.1.2. Deep Brain Stimulators Parkinson’s Disease Depression
5.1.3. Spinal Cord Stimulators Failed Back Syndrome Ischemia
5.1.4. Vagus Nerve Stimulators Epilepsy
5.1.5. Cochlear Implants Sensorineural Hearing Loss
5.1.6. Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators) Urinary Incontinence Treatment-Resistant Depression
5.2. Japan Electroceuticals Market by End-Users
5.2.1. Hospitals and Clinics
5.2.2. Research Institutes
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Boston Scientific Corp.
6.3. Century Medical, Inc.
6.4. Demant A/S
6.5. Edwards Lifesciences Corp.
6.6. Getinge AB
6.7. GlaxoSmithKline PLC
6.8. Livanova PLC
6.9. Medtronic PLC
6.10. Renishaw PLC
6.11. Sonova Holding AG
6.12. Sorin CRM SAS
6.13. Terumo Corp.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Boston Scientific Corp.
  • Century Medical, Inc.
  • Demant A/S
  • Edwards Lifesciences Corp.
  • Getinge AB
  • GlaxoSmithKline PLC
  • Livanova PLC
  • Medtronic PLC
  • Renishaw PLC
  • Sonova Holding AG
  • Sorin CRM SAS
  • Terumo Corp.